Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Amoxicillin-clavulanate→

Amoxicillin Clavulanate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
79198-29-1
PubChem CID
6435924
Molecular formula
C24H28N4O10S
Molecular weight
564.6 g/mol
Drug class
Combination antibacterial: aminopenicillin (amoxicillin) plus beta-lactamase inhibitor (clavulanic acid)
Mechanism of action
Amoxicillin binds penicillin-binding proteins and inhibits bacterial peptidoglycan cell-wall synthesis, causing cell-wall weakening and lysis. Clavulanic acid inactivates certain beta-lactamases and protects amoxicillin from enzymatic degradation; it has no clinically useful antibacterial action alone.
Indications / reported uses
  • Treatment of infections caused by susceptible organisms, including selected respiratory, ear/nose/throat, urinary, skin/soft-tissue, dental and bone/joint infections; the exact indications vary by strength, formulation and local product information

Sources: UK SmPC — Co-amoxiclav 500 mg/125 mg · UK SmPC — Co-amoxiclav 875 mg/125 mg · NCBI Bookshelf — Amoxicillin/clavulanate pharmacology · FDA product information

Identification source: PubChem record (CID 6435924). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Combination antibacterial: aminopenicillin (amoxicillin) plus beta-lactamase inhibitor (clavulanic acid)

Mechanism of action

Amoxicillin binds penicillin-binding proteins and inhibits bacterial peptidoglycan cell-wall synthesis, causing cell-wall weakening and lysis. Clavulanic acid inactivates certain beta-lactamases and protects amoxicillin from enzymatic degradation; it has no clinically useful antibacterial action alone.

General use cases

  • Treatment of infections caused by susceptible organisms, including selected respiratory, ear/nose/throat, urinary, skin/soft-tissue, dental and bone/joint infections; the exact indications vary by strength, formulation and local product information

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Amoxicillin Clavulanate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Amoxicillin Clavulanate Permitted Daily Exposure (PDE) report (the Amoxicillin Clavulanate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Amoxicillin Clavulanate Occupational Exposure Limit (OEL) report (the Amoxicillin Clavulanate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.